source
- Leerink analyst downgrades Bristol Myers over pipeline concernsA Leerink analyst signaled new bearishness on Bristol Myers Squibb, downgrading the company's stock rating. Analyst David Risinger moved the rating from outperform to a lower stance, saying he is…
- Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setbackIn September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks. Viking reported Phase 1 r…